IGSF8 expression differentially modifies response to immunotherapy in metastatic melanoma

IGSF8 identified as novel immune checkpoint modifying IO outcomes stratified by Tempus IPS

INDICATION
Melanoma
BIOMARKER
IGSF8

 

Kaplan-Meier survival curves comparing rwOS between High- and Low-IGSF8 expression groups, stratified by IPS status (High or Low), in pre-treatment samples from patients with malignant melanoma undergoing first-line (1L) immunotherapy (IO) monotherapy. Shaded areas represent the 95% confidence intervals. Median survival times are specified. Cohort was divided based on the median IGSF8 expression level.

 

Related cases

Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Abstract pattern of varying density purple dots on a white grid background.

LAG3 expression as a predictive biomarker for 1L ICI in melanoma

2025-10-09
Melanoma
LAG3
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Abstract grid of squares showing color gradients and clustered data points.

Shorter Pluvicto treatment course for patients with prostate cancer and high initial PSA

PSA
Prostate
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Visualization showing multiple rows of blue and orange squares, divided by a black dotted line.

Genomic and transcriptomic differences between early-onset and non-early-onset PDAC

2026-07-01
Pancreatic
KRAS
BRCA2
SMAD4
CDKN2A